Targinta

Targinta is a preclinical-stage biotech focused on novel targeted therapies for aggressive, hard-to-treat cancers. Its core asset is the proprietary target integrin α10β1, against which it is developing two lead candidates: TARG9, an ADC, and TARG10, a functional blocking antibody. The company is a wholly-owned subsidiary of the publicly traded parent company Xintela AB, leveraging this structure for funding and research support as it advances its programs toward clinical trials.

Proprietary targeted antibody platform based on the novel cancer target integrin α10β1, a collagen-binding receptor highly expressed in aggressive solid tumors (e.g., glioblastoma, triple-negative breast cancer) with low expression in normal tissues. The platform enables development of both functional blocking monoclonal antibodies and antibody-drug conjugates (ADCs), leveraging the target's efficient internalization.

Targinta competes in the crowded field of targeted oncology, specifically in ADC development for solid tumors. It faces competition from large pharma (e.g., AstraZeneca, Roche) and numerous biotechs with various target and payload technologies. Its differentiation hinges entirely on the novelty and clinical validity of its integrin α10β1 target, which is not widely pursued by competitors.